Solvent-Free Abraxane(R) Combined With Targeted Therapy Bevacizumab Evaluated As Firs

[News]

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, announced the presentation of results from an ongoing single-arm, open-label, Phase II clinical trial evaluating solvent-free ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) in combination with bevacizumab for the first-line treatment of metastatic breast cancer.

More... (http://www.medicalnewstoday.com/articles/109593.php)